Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Norelgestromin/Ethinylestradiol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016) | DRUG | 0.55mg ethinylestradiol and 2.1mg gestodene |
| Norelgestromin/Ethinylestradiol (EVRA) | DRUG | 0.6mg ethinylestradiol and 6mg norelgestromin |
Inclusion Criteria: * Healthy women requesting contraception aged 18-35 years old * Smokers must not be older than 30 at time of informed consent * History of regular cyclic menstrual periods, normal cervical smear Exclusion Criteria: * Pregnancy or lactation * Obesity (BMI\>30), hypersensitivity...
Norelgestromin/Ethinylestradiol is a combination hormonal contraceptive used to prevent pregnancy. It is being developed as a birth control patch for use in women. The drug is currently in Phase 3 clinical development for the indication of contraception.
Norelgestromin/Ethinylestradiol is being developed by Bayer AG, a pharmaceutical company traded on the OTC market under the ticker BAYRY. The drug is in Phase 3 clinical development for contraception.
Norelgestromin/Ethinylestradiol is in Phase 3 clinical development. It is an investigational drug for contraception and has not been approved by regulatory authorities. A Phase 3 clinical trial for the drug has been completed.
Norelgestromin/Ethinylestradiol has one completed Phase 3 clinical trial, identified as NCT00984789, titled "Birth Control Patch Study." The trial enrolled 393 female participants aged 18 years and older and was conducted in Austria, Czechia, and the Netherlands.
Norelgestromin/Ethinylestradiol is a combination of two hormones, norelgestromin and ethinylestradiol, which work together to prevent ovulation and thicken cervical mucus, making it harder for sperm to reach an egg. It is delivered through a patch applied to the skin.